Related Experiment Video
Updated: May 25, 2026
12:33
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
The alpha-cell as target for type 2 diabetes therapy.
Mikkel Christensen1, Jonatan I Bagger, Tina Vilsbøll
1Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark.
The Review of Diabetic Studies : RDS
|January 21, 2012
Summary
Targeting pancreatic alpha-cells and glucagon offers a potential treatment for type 2 diabetes. However, glucagon receptor antagonists face safety issues, making GLP-1 based agents more favorable for controlling alpha-cell activity.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Glucagon, secreted by pancreatic alpha-cells, maintains glucose homeostasis by stimulating hepatic glucose production.
- Elevated glucagon levels in type 2 diabetes significantly contribute to hyperglycemia.
- The pancreatic alpha-cell and glucagon are recognized as therapeutic targets for type 2 diabetes management.
Purpose of the Study:
- To review the physiological role of glucagon.
- To outline glucagon's involvement in type 2 diabetes pathophysiology.
- To discuss the therapeutic potential, advantages, and limitations of targeting glucagon secretion or its receptor for type 2 diabetes treatment.
Main Methods:
- Review of preclinical and clinical evidence on glucagon-targeting therapies.
- Analysis of existing and developing drugs for glucagon suppression or receptor antagonism.
- Discussion of safety profiles and efficacy of different therapeutic approaches.
Main Results:
- Glucagon receptor antagonists present significant safety concerns.
- Pharmacological agents leveraging GLP-1's glucose-dependent glucagonostatic effects show promise.
- Current evidence suggests GLP-1 based therapies are a more favorable approach to modulate alpha-cell function in type 2 diabetes.
Conclusions:
- Novel glucagon receptor antagonists face safety challenges.
- GLP-1 based therapies offer a safer and effective strategy for alpha-cell constraint in type 2 diabetes.
- Modulating alpha-cell activity through GLP-1 mechanisms represents the most promising therapeutic avenue currently.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:36Carbohydrate Metabolism
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...